RT Journal Article SR Electronic T1 Why are only 50% of courses of anti-tumor necrosis factor agents continued for only 2 years in some settings? Need for longterm observations in standard care to complement clinical trials. JF The Journal of Rheumatology JO J Rheumatol FD The Journal of Rheumatology SP 2372 OP 2375 VO 33 IS 12 A1 Theodore Pincus A1 Yusuf Yazici A1 Ronald van Vollenhoven YR 2006 UL http://www.jrheum.org/content/33/12/2372.abstract AB